AMCP submitted comments on the proposed FDA Prescription Drug User Fee Act Reauthorization commitment letter, supporting the agency's plans to increase resources for approval of cell and gene therapies and continued exploration of uses for real-world evidence in regulatory decision-making.
On Sept. 14, AMCP joined a Medicaid stakeholder letter urging Congress to include language that requires 12-month continuous eligibility for children on Medicaid and the Children’s Health Insurance Program (CHIP) in the reconciliation bill.
AMCP is pleased to announce that Jennifer S. Graff, PharmD, has joined the organization as senior director, professional affairs. Dr. Graff will lead strategic efforts for AMCP’s practice-related initiatives and work to advance patient outcomes and medication management strategies.
A group of 14 health care organizations in and around Washington, D.C. issued a joint statement making COVID vaccination a condition of returning to work in their respective offices.
September 2021 News & Views: AMCP Strategic Priorities Quarterly Update; Why We Chose to be In-Person for AMCP Nexus 2021; AMCP Statement on Allowing Pharmacists to Administer REGEN-COV; Register for AMCP Foundation’s 5K For the Future.